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OBJECTIVE: To evaluate the cost-effectiveness of intravitreal
bevacizumab to ranibizumab in patients with neovascular AMD.
METHODS: A Markov Model was constructed to evaluate
incremental cost-effectiveness ratios (ICER, $/quality-adjusted
life years (QALY)) between bevacizumab and ranibizumab.
Transitional probabilities for ranibizumab were extrapolated
from two published trials, while bevacizumab probabilities were
derived using a weighted mean average of institutional clinical
outcome data as well as published studies. Utility values were
obtained from a published source. Mortality rates were deter-
mined from the Centers for Disease Control (CDC) 2003 Life
Tables. A payer perspective was taken with resource utilization
and total direct costs estimated using the Centers for Medicare
and Medicaid Services and VASDHS Decision Support System
cost data. One-thousand patients with a baseline age of 65 and
AMD diagnosis were simulated through the model for 20 years.
Sensitivity analyses were performed using univariate and proba-
bilistic sensitivity analysis (PSA) on all costs, transition probabili-
ties and utility scores. Utilities and transitional probabilities were
subject to a sensitivity analysis using beta distribution and cost
by gamma distribution. An acceptability curve was calculated to
determine the probability of cost-effectiveness of bevacizumab
to ranibizumab. RESULTS: The average cost-effectiveness ratio
(CER) for bevacizumab was $2,454 per QALY compared to
$12,327 per QALY for ranibizumab. The ICER for ranibizumab
was $258,355 for each additional QALY gained. The univariate
analysis determined the two treatments were sensitive to drug
cost. The break even point for equivalent CER was $208 for
ranibizumab (varying drug costs) and $2399 for bevacizumab
(varying drug costs). The PSA revealed an 89.8% probability of
bevacizumab being more cost-effective with a Willingness-to-Pay
(WTP). CONCLUSION: Based on a WTP deﬁned at $50,000 per
QALY, bevacizumab was more cost-effective than ranibizumab
89.8% of the time due to lower acquisition costs.
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OBJECTIVE: The purpose of the research was to conduct a
cost-effectiveness model in order to analyze the value of Pegap-
tanib and Ranibizumab on the basis of the information and
resources from the previous studies. METHODS: The costs
of these modalities of AMD were calculated from published
sources. The total costs included consumptions of medical
resources and non-medical resources for AMD treatment. The
annual unit drug costs were collected from the Red Book 2007
and were multiplied by administrations per year. The efﬁcacy was
deﬁned as the loss of fewer than 15 letters from baseline visual
acuity within a year with recommendation dosage. The analysis
model was compared with placebo. We calculated Incremental
Cost Effectiveness Ratio (ICER) and plotted the cost-effectiveness
result. RESULTS: With a basic decision analysis, considering the
probability and costs of the three treatment options, the base
estimate of one year of total cost was $13,066 per person from
the pegaptanib treatment, and $31,564 for ranibizumab. The
total expected cost for placebo was $3152. The result in the
ICER model shows that pegaptanib costs $10,746 per year to get
only about 12% improvement in effectiveness compared to
placebo, while ranibizumab costs $29,244 to gain about 37%
improvement over placebo. Thus, compared to placebo, the
ICER is $934,433 per unit increase in effectiveness when patients
are treated by pegaptanib, and $80,121 in ranibizumab. CON-
CLUSION: Based on this cost-effectiveness model, both anti-
VEGF agents are costly. Ranibizumab has higher probability of
success versus in pegaptanib therapy (0.7 for pegaptanib vs. 0.95
for ranibizumab). However, the price of ranibizumab is much
higher than pegaptanib. The ICER model suggests that ranibi-
zumab maybe the ﬁrst consideration of anti-VEGF drugs because
based on this model, the ICER of ranibizumab is lower than
pegaptanib. In future studies, there should be more investigations
of quality-of-life factors.
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COST-EFFECTIVENESS OFTHETREATMENT FOR MODERATE
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OBJECTIVE: Psoriasis is a dermatological disease with major
consequences on the quality of life of patients. Biological treat-
ments for this disease have an effectiveness which is equivalent to
that of conventional drugs with fewer side effects. The objective of
this analysis was to evaluate the cost-effectiveness of the treatment
for moderate to severe psoriasis from an institutional perspective
in Mexico. METHODS: To compare the cost and the effective-
ness, a decision tree model was structured with a temporary
horizon of 12 weeks. Only costs per drug were considered for this
analysis, as the rest of the costs are similar for institutional buyers.
Comparators: inﬂiximab 5mg/kg given at weeks 0, 2, and 6;
etanercept 25 mg twice weekly, etanercept 50 mg twice weekly
and efalizumab 1mg/kg weekly. Effectiveness measure: percentage
of patients with a PASI 75 (Psoriasis Area and Severity Index)
response. Costs were estimated using prices of 2007, and an
exchange rate of x pesos/dollar was used. Costs were estimated
using 2007 prices and are expressed in USD (exchange rate of
10.93 pesos per USD). RESULTS: Costs expected per treatment
type are: $6987 inﬂiximab, $6422.70 efalizumab, $5555.40 etan-
ercept 50 mg and $2777.70 etanercept 25 mg. The percentage of
patients achieving a PASI 75 response per treatment type is: 84%
for inﬂiximab, 49% for etanercept 50 mg, 33% for etanercept
25 mg and 28% for efalizumab. The following ICERs were
obtained for inﬂiximab: $1007.70 vs. efalizumab, $8253.50 vs.
etanercept 25 mg and $4090.50 vs. etanercept 50 mg. In the three
cases, ICERs are less than three times the GDP per capita in
Mexico. CONCLUSION: Inﬂiximab is a cost-effective drug for
the treatment of moderate to severe psoriasis.
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THE COST-EFFECTIVENESS OF RANIBIZUMAB (LUCENTIS®)
INTREATING PATIENTSWITH PREDOMINANTLY CLASSIC,
MINIMALLY CLASSIC,AND OCCULT NEOVASCULAR
AGE-RELATED MACULAR DEGENERATION (AMD)
Turpcu A, Hay JW
University of Southern California, Los Angeles, CA, USA
OBJECTIVE: Using a societal perspective, to evaluate the cost-
effectiveness of Lucentis compared to Visudyne Photodynamic
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